Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Gemcitabine/Osimertinib/Paclitaxel: Acquired drug resistance and lack of efficacy: case report.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
A 62-year-old woman with pancreatic ductal adenocarcinoma (PDAC) experienced lack of efficacy with gemcitabine and paclitaxel treatment, as well as acquired drug resistance to osimertinib. Despite a good initial response to neoadjuvant chemotherapy, her disease progressed to the liver and bones. After switching to osimertinib, a biopsy confirmed persistent metastatic PDAC, leading to a change in treatment regimen that ultimately improved her condition. The woman's quality of life remained high as she continued chemotherapy with a modified drug combination. [Extracted from the article]
- Abstract:
Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.